Drug Profile
Japanese encephalitis vaccine - KM Biologics
Alternative Names: Encevac; Jeimmugen Inj1; KD-287; Vero Cell-derived Inactivated Japanese Encephalitis Vaccine KD-287Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Kaketsuken
- Developer Astellas Pharma; Boryung Pharmaceutical; KM Biologics
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Japanese encephalitis
Most Recent Events
- 01 Aug 2019 KM Biologics enters into a distribution agreement with Meiji Seika Pharma for its human vaccines portfolio (9307110; 9258921)
- 31 Jul 2019 Astellas Pharma and KM Biologics agreement for human vaccines expires (9307110; 9258921)
- 01 Feb 2013 Boryung Pharmaceutical completes a phase III trial in Japanese encephalitis (infants; prevention) in South Korea (NCT01150942)